Tetravalent SARS-CoV-2 S1 subunit protein vaccination elicits robust humoral and cellular immune responses in SIV-infected rhesus macaque controllers
IMPORTANCE: The study provides important insights into the immunogenicity and efficacy of a tetravalent protein subunit vaccine candidate against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The vaccine induced both humoral and cellular immune responses in nonhuman primates with controlled SIVagm infection and was able to generate Omicron variant-specific antibodies without specifically vaccinating with Omicron. These findings suggest that the tetravalent composition of the vaccine candidate could provide broad protection against multiple SARS-CoV-2 variants while minimizing the risk of immune escape and the emergence of new variants. Additionally, the use of rhesus macaques with controlled SIVsab infection may better represent vaccine immunogenicity in humans with chronic viral diseases, highlighting the importance of preclinical animal models in vaccine development. Overall, the study provides valuable information for the development and implementation of coronavirus disease 2019 vaccines, particularly for achieving global vaccine equity and addressing emerging variants.
| Errataetall: | |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:14 |
|---|---|
| Enthalten in: |
mBio - 14(2023), 5 vom: 31. Okt., Seite e0207023 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Khan, Muhammad S [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 25.12.2023 Date Revised 10.02.2024 published: Print-Electronic UpdateOf: bioRxiv. 2023 Mar 16;:. - PMID 36993692 Citation Status MEDLINE |
|---|
| doi: |
10.1128/mbio.02070-23 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM363237682 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM363237682 | ||
| 003 | DE-627 | ||
| 005 | 20240210232734.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1128/mbio.02070-23 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1286.xml |
| 035 | |a (DE-627)NLM363237682 | ||
| 035 | |a (NLM)37830800 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Khan, Muhammad S |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Tetravalent SARS-CoV-2 S1 subunit protein vaccination elicits robust humoral and cellular immune responses in SIV-infected rhesus macaque controllers |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 25.12.2023 | ||
| 500 | |a Date Revised 10.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a UpdateOf: bioRxiv. 2023 Mar 16;:. - PMID 36993692 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a IMPORTANCE: The study provides important insights into the immunogenicity and efficacy of a tetravalent protein subunit vaccine candidate against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The vaccine induced both humoral and cellular immune responses in nonhuman primates with controlled SIVagm infection and was able to generate Omicron variant-specific antibodies without specifically vaccinating with Omicron. These findings suggest that the tetravalent composition of the vaccine candidate could provide broad protection against multiple SARS-CoV-2 variants while minimizing the risk of immune escape and the emergence of new variants. Additionally, the use of rhesus macaques with controlled SIVsab infection may better represent vaccine immunogenicity in humans with chronic viral diseases, highlighting the importance of preclinical animal models in vaccine development. Overall, the study provides valuable information for the development and implementation of coronavirus disease 2019 vaccines, particularly for achieving global vaccine equity and addressing emerging variants | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a cellular immunity | |
| 650 | 4 | |a efficacy | |
| 650 | 4 | |a humoral immunity | |
| 650 | 4 | |a immunogenicity | |
| 650 | 4 | |a nonhuman primate | |
| 650 | 4 | |a protein subunit | |
| 650 | 4 | |a tetravalent | |
| 650 | 4 | |a vaccines | |
| 650 | 7 | |a COVID-19 Vaccines |2 NLM | |
| 650 | 7 | |a Antibodies, Viral |2 NLM | |
| 650 | 7 | |a Antibodies, Neutralizing |2 NLM | |
| 650 | 7 | |a Spike Glycoprotein, Coronavirus |2 NLM | |
| 650 | 7 | |a spike protein, SARS-CoV-2 |2 NLM | |
| 700 | 1 | |a Kim, Eun |e verfasserin |4 aut | |
| 700 | 1 | |a Le Hingrat, Quentin |e verfasserin |4 aut | |
| 700 | 1 | |a Kleinman, Adam |e verfasserin |4 aut | |
| 700 | 1 | |a Ferrari, Alessandro |e verfasserin |4 aut | |
| 700 | 1 | |a Sammartino, Jose C |e verfasserin |4 aut | |
| 700 | 1 | |a Percivalle, Elena |e verfasserin |4 aut | |
| 700 | 1 | |a Xu, Cuiling |e verfasserin |4 aut | |
| 700 | 1 | |a Huang, Shaohua |e verfasserin |4 aut | |
| 700 | 1 | |a Kenniston, Thomas W |e verfasserin |4 aut | |
| 700 | 1 | |a Cassaniti, Irene |e verfasserin |4 aut | |
| 700 | 1 | |a Baldanti, Fausto |e verfasserin |4 aut | |
| 700 | 1 | |a Pandrea, Ivona |e verfasserin |4 aut | |
| 700 | 1 | |a Gambotto, Andrea |e verfasserin |4 aut | |
| 700 | 1 | |a Apetrei, Cristian |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t mBio |d 2010 |g 14(2023), 5 vom: 31. Okt., Seite e0207023 |w (DE-627)NLM200128191 |x 2150-7511 |7 nnns |
| 773 | 1 | 8 | |g volume:14 |g year:2023 |g number:5 |g day:31 |g month:10 |g pages:e0207023 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1128/mbio.02070-23 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 14 |j 2023 |e 5 |b 31 |c 10 |h e0207023 | ||